Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| EQUIFAX INCEFX · Entity 3235 | Director · CEO | July 24, 2026 | July 28, 2026 |
| FAIR ISAAC CORPFICO · Entity 3206 | Director | March 21, 2018 | March 22, 2018 |
| GENERAL ELECTRIC COGE · Entity 2813 | Senior Vice President | February 22, 2006 | February 24, 2006 |
| NCR Voyix CorpNCR · Entity 293 | Director | September 29, 2023 | October 03, 2023 |
| RAYMOND JAMES FINANCIAL INCRJF · Entity 3126 | Director | February 19, 2026 | February 23, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
EQUIFAX INC
Report date July 24, 2026 · Filed July 28, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 271,890 |
Last balance in matching sequence
After 2026-07-24 transaction · row 9
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
9 source rowsRow 1 · 2026-07-24 · Exercise / conversion · Acquired 37,791 · Balance 309,681 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 10/28/2025. F2: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 226 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan. Row 2 · 2026-07-24 · Sale · Disposed 500 · Balance 309,181 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 10/28/2025. F3: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $175.74 to $175.94, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. F2: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 226 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan. Row 3 · 2026-07-24 · Sale · Disposed 600 · Balance 308,581 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 10/28/2025. F4: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $169.42 to $170.09, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. F2: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 226 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan. Row 4 · 2026-07-24 · Sale · Disposed 600 · Balance 307,981 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 10/28/2025. F5: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $168.395 to $168.55, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. F2: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 226 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan. Row 5 · 2026-07-24 · Sale · Disposed 1,300 · Balance 306,681 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 10/28/2025. F6: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $174.54 to $175.48, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. F2: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 226 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan. Row 6 · 2026-07-24 · Sale · Disposed 2,936 · Balance 303,745 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 10/28/2025. F7: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $173.50 to $174.15, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. F2: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 226 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan. Row 7 · 2026-07-24 · Sale · Disposed 4,112 · Balance 299,633 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 10/28/2025. F8: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $172.50 to $173.33, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. F2: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 226 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan. Row 8 · 2026-07-24 · Sale · Disposed 6,200 · Balance 293,433 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 10/28/2025. F9: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $170.48 to $171.47, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. F2: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 226 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan. Row 9 · 2026-07-24 · Sale · Disposed 21,543 · Balance 271,890 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 10/28/2025. F10: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $171.50 to $172.49, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. F2: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 226 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan. |
| Stock Option/Right to BuySEC Table II · derivative / convertible security · Conversion / exercise price $112.46 · Expires 2028-05-04 | Direct | 37,792 |
Reported balance
After 2026-07-24 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2026-07-24 · Exercise / conversion · Disposed 37,791 · Balance 37,792 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 10/28/2025. F11: The option vested in three equal annual increments beginning 5/4/2019. |
| Common StockSEC Table I · non-derivative | Indirect2-yr Apr 2025 GRAT | 2,350 |
Reported balance
Holding disclosure · report date 2026-07-24 · row 10
Holding and transaction disclosures are not merged.
1 source rowRow 10 · Balance 2,350 |
| Common StockSEC Table I · non-derivative | Indirect2-yr Dec 2025 GRAT | 21,284 |
Reported balance
Holding disclosure · report date 2026-07-24 · row 11
Holding and transaction disclosures are not merged.
1 source rowRow 11 · Balance 21,284 |
| Common StockSEC Table I · non-derivative | Indirect2-yr Jun 2025 GRAT | 38,332 |
Reported balance
Holding disclosure · report date 2026-07-24 · row 12
Holding and transaction disclosures are not merged.
1 source rowRow 12 · Balance 38,332 |
| Common StockSEC Table I · non-derivative | Indirect2-yr May 2025 GRAT | 2,018 |
Reported balance
Holding disclosure · report date 2026-07-24 · row 13
Holding and transaction disclosures are not merged.
1 source rowRow 13 · Balance 2,018 |
| Common StockSEC Table I · non-derivative | Indirect2-yr May 2026 GRAT | 18,562 |
Reported balance
Holding disclosure · report date 2026-07-24 · row 14
Holding and transaction disclosures are not merged.
1 source rowRow 14 · Balance 18,562 |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 10/28/2025.
F2: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 226 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan.
F3: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $175.74 to $175.94, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided.
F4: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $169.42 to $170.09, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided.
F5: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $168.395 to $168.55, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided.
F6: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $174.54 to $175.48, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided.
F7: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $173.50 to $174.15, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided.
F8: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $172.50 to $173.33, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided.
F9: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $170.48 to $171.47, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided.
F10: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $171.50 to $172.49, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided.
F11: The option vested in three equal annual increments beginning 5/4/2019.
FAIR ISAAC CORP
Report date March 21, 2018 · Filed March 22, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,174 |
Reported balance
After 2018-03-21 transaction · row 1
1 source rowRow 1 · 2018-03-21 · Exercise / conversion · Acquired 1,587 · Balance 3,174 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Expires 2019-03-21 | Direct | 1,586 |
Reported balance
After 2018-03-21 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-03-21 · Exercise / conversion · Disposed 1,587 · Balance 1,586 F1: Each restricted stock unit represents a right to receive one share of Fair Isaac common stock contingent upon continued service on the board. F2: The restricted stock units vest in three equal annual installments commencing on this date and vested shares will be delivered to the reporting person as soon as practicable thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a right to receive one share of Fair Isaac common stock contingent upon continued service on the board.
F2: The restricted stock units vest in three equal annual installments commencing on this date and vested shares will be delivered to the reporting person as soon as practicable thereafter.
GENERAL ELECTRIC CO
Report date February 22, 2006 · Filed February 24, 2006
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Phantom Stock UnitsSEC Table II · derivative / convertible security | Direct | 7,283 |
Reported balance
After 2006-02-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2006-02-22 · Grant · Acquired 1,057 · Balance 7,283 F1: 1-for-1 F2: Reallocable to other investment media. Payable after termination of employment. Total includes accrued dividends. |
Filing footnotes · ownership attribution and instrument terms
F1: 1-for-1
F2: Reallocable to other investment media. Payable after termination of employment. Total includes accrued dividends.
NCR Voyix Corp
Report date September 29, 2023 · Filed October 03, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Phantom Stock UnitsSEC Table II · derivative / convertible security | Direct | 951 |
Reported balance
After 2023-09-29 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-09-29 · Grant · Acquired 951 · Balance 951 F1: These are stock units acquired under the NCR Director Compensation Program (the "Compensation Program") as part of the reporting person's annual retainer, which is paid quarterly. The reporting person elected to defer receipt of the annual retainer in accordance with the terms of the Compensation Program. F2: The phantom stock units are converted into common stock on a one-for-one basis. F3: The phantom stock units become payable in common stock following the reporting person's termination of service as a director. |
Filing footnotes · ownership attribution and instrument terms
F1: These are stock units acquired under the NCR Director Compensation Program (the "Compensation Program") as part of the reporting person's annual retainer, which is paid quarterly. The reporting person elected to defer receipt of the annual retainer in accordance with the terms of the Compensation Program.
F2: The phantom stock units are converted into common stock on a one-for-one basis.
F3: The phantom stock units become payable in common stock following the reporting person's termination of service as a director.
RAYMOND JAMES FINANCIAL INC
Report date February 19, 2026 · Filed February 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,285 |
Reported balance
After 2026-02-19 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-02-19 · Grant · Acquired 1,303 · Balance 2,285 F1: Consists of a grant of Deferred Restricted Stock Units ("DRSUs") as part of compensation for service on the registrant's Board of Directors. Upon vesting, the DRSUs convert to the right to receive shares of common stock on a one-to-one basis, together with accrued cash in lieu of dividends. The DRSUs vest at the date of the next succeeding annual shareholders meeting following the grant date, but no later than March 15 of the calendar year following grant. Pursuant to an irrevocable election by the reporting person, settlement of the DRSUs will be deferred following vesting until the date the reporting person terminates his or her service on the Board of Directors. F2: Includes DRSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of a grant of Deferred Restricted Stock Units ("DRSUs") as part of compensation for service on the registrant's Board of Directors. Upon vesting, the DRSUs convert to the right to receive shares of common stock on a one-to-one basis, together with accrued cash in lieu of dividends. The DRSUs vest at the date of the next succeeding annual shareholders meeting following the grant date, but no later than March 15 of the calendar year following grant. Pursuant to an irrevocable election by the reporting person, settlement of the DRSUs will be deferred following vesting until the date the reporting person terminates his or her service on the Board of Directors.
F2: Includes DRSUs.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
NCR Atleos Corp
Report date May 21, 2025 · Filed May 23, 2025
Section 16 reporting ended · disclosed 2025-05-23. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 31,475 |
Reported balance
After 2025-05-21 transaction · row 1
1 source rowRow 1 · 2025-05-21 · Exercise / conversion · Acquired 2,690 · Balance 31,475 F1: These phantom stock units vested on May 21, 2025, in accordance with the reporting person's deferral election under the NCR Atleos Director Compensation Program. |
Filing footnotes · ownership attribution and instrument terms
F1: These phantom stock units vested on May 21, 2025, in accordance with the reporting person's deferral election under the NCR Atleos Director Compensation Program.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 29, 2022 Filed Aug 2, 2022 21:30 UTC | EQUIFAX INC EFX · Entity 3235 | GrantCommon Stock | 23,934 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-009135 · doc4.xml · nonDerivative · entry 1 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,798 F1 · security: Special equity grant pursuant to the Company's long-term incentive plan. The award of restricted stock vests 100% on 12/31/2025. F2 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date. Read SEC document |
| June 30, 2022 Filed Jul 1, 2022 20:04 UTC | NCR Voyix Corp NCR · Entity 293 | GrantPhantom Stock Units · Derivative | 1,427 | $31.11 | $44,393.97 |
DisclosureSEC source: 0001209191-22-040192 · doc4.xml · derivative · entry 1 Begor Mark W · CIK 0001335111 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,427 Underlying: Common Stock · 1,427 shares Expires not disclosed F1 · security: These are stock units acquired under the NCR Director Compensation Program (the "Compensation Program") as part of the reporting person's annual retainer, which is paid quarterly. The reporting person elected to defer receipt of the annual retainer in accordance with the terms of the Compensation Program. F2 · derivative.exercise_price: The phantom stock units are converted into common stock on a one-for-one basis. F3 · derivative.exercise_date: The phantom stock units become payable in common stock following the reporting person's termination of service as a director. F3 · derivative.expiration_date: The phantom stock units become payable in common stock following the reporting person's termination of service as a director. Read SEC document |
| May 02, 2022 Filed May 4, 2022 20:39 UTC | NCR Voyix Corp NCR · Entity 293 | GrantCommon Stock | 6,479 | $34.73 | $225,015.67 |
DisclosureSEC source: 0001209191-22-027117 · doc4.xml · nonDerivative · entry 1 Begor Mark W · CIK 0001335111 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,275 F1 · shares: These restricted stock units represent the annual equity grant awarded to directors under the NCR Director Compensation Program (the "Compensation Program"). The restricted stock units vest in four equal quarterly installments beginning three months after the grant date, subject to the reporting person's continued service as a director on each vesting date. The reporting person elected to defer receipt of NCR common stock underlying the restricted stock units in accordance with the terms of the Compensation Program. The reporting person will receive NCR common stock following the termination of the reporting person's service as a director. Read SEC document |
| April 27, 2022 Filed Apr 28, 2022 20:13 UTC | EQUIFAX INC EFX · Entity 3235 | SaleCommon Stock | 3,869 | $203.63 | $787,857.24 |
DisclosureSEC source: 0001225208-22-006227 · doc4.xml · nonDerivative · entry 10 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,692 F1 · kind: The sales reported in this Form 4 were effected pursuant to a rule 10b5-1 trading plan adopted by the reporting person on 2/16/2022. F12 · price: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $203.30 to $204.17, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. F3 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date. Read SEC document |
| April 27, 2022 Filed Apr 28, 2022 20:13 UTC | EQUIFAX INC EFX · Entity 3235 | SaleCommon Stock | 2,225 | $204.70 | $455,447.93 |
DisclosureSEC source: 0001225208-22-006227 · doc4.xml · nonDerivative · entry 9 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,561 F1 · kind: The sales reported in this Form 4 were effected pursuant to a rule 10b5-1 trading plan adopted by the reporting person on 2/16/2022. F11 · price: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $204.31 to $205.29, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. F3 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date. Read SEC document |
| April 27, 2022 Filed Apr 28, 2022 20:13 UTC | EQUIFAX INC EFX · Entity 3235 | SaleCommon Stock | 2,147 | $202.90 | $435,634.46 |
DisclosureSEC source: 0001225208-22-006227 · doc4.xml · nonDerivative · entry 8 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,786 F1 · kind: The sales reported in this Form 4 were effected pursuant to a rule 10b5-1 trading plan adopted by the reporting person on 2/16/2022. F10 · price: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $202.2975 to $203.20, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. F3 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date. Read SEC document |
| April 27, 2022 Filed Apr 28, 2022 20:13 UTC | EQUIFAX INC EFX · Entity 3235 | SaleCommon Stock | 1,962 | $205.76 | $403,702.89 |
DisclosureSEC source: 0001225208-22-006227 · doc4.xml · nonDerivative · entry 7 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,933 F1 · kind: The sales reported in this Form 4 were effected pursuant to a rule 10b5-1 trading plan adopted by the reporting person on 2/16/2022. F9 · price: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $205.315 to $206.29, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. F3 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date. Read SEC document |
| April 27, 2022 Filed Apr 28, 2022 20:13 UTC | EQUIFAX INC EFX · Entity 3235 | SaleCommon Stock | 1,150 | $201.68 | $231,933.73 |
DisclosureSEC source: 0001225208-22-006227 · doc4.xml · nonDerivative · entry 6 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,895 F1 · kind: The sales reported in this Form 4 were effected pursuant to a rule 10b5-1 trading plan adopted by the reporting person on 2/16/2022. F8 · price: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $201.28 to $202.275, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. F3 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date. Read SEC document |
| April 27, 2022 Filed Apr 28, 2022 20:13 UTC | EQUIFAX INC EFX · Entity 3235 | SaleCommon Stock | 995 | $209.73 | $208,683.54 |
DisclosureSEC source: 0001225208-22-006227 · doc4.xml · nonDerivative · entry 5 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,045 F1 · kind: The sales reported in this Form 4 were effected pursuant to a rule 10b5-1 trading plan adopted by the reporting person on 2/16/2022. F7 · price: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $209.45 to $210.29, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. F3 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date. Read SEC document |
| April 27, 2022 Filed Apr 28, 2022 20:13 UTC | EQUIFAX INC EFX · Entity 3235 | SaleCommon Stock | 992 | $206.87 | $205,212.26 |
DisclosureSEC source: 0001225208-22-006227 · doc4.xml · nonDerivative · entry 4 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,040 F1 · kind: The sales reported in this Form 4 were effected pursuant to a rule 10b5-1 trading plan adopted by the reporting person on 2/16/2022. F6 · price: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $206.37 to $207.35, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. F3 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date. Read SEC document |
| April 27, 2022 Filed Apr 28, 2022 20:13 UTC | EQUIFAX INC EFX · Entity 3235 | SaleCommon Stock | 741 | $208.73 | $154,671.52 |
DisclosureSEC source: 0001225208-22-006227 · doc4.xml · nonDerivative · entry 3 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,032 F1 · kind: The sales reported in this Form 4 were effected pursuant to a rule 10b5-1 trading plan adopted by the reporting person on 2/16/2022. F5 · price: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $208.41 to $209.11, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. F3 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date. Read SEC document |
| April 27, 2022 Filed Apr 28, 2022 20:13 UTC | EQUIFAX INC EFX · Entity 3235 | SaleCommon Stock | 490 | $207.71 | $101,775.74 |
DisclosureSEC source: 0001225208-22-006227 · doc4.xml · nonDerivative · entry 2 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,773 F1 · kind: The sales reported in this Form 4 were effected pursuant to a rule 10b5-1 trading plan adopted by the reporting person on 2/16/2022. F4 · price: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $207.38 to $208.24, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. F3 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date. Read SEC document |
| April 27, 2022 Filed Apr 28, 2022 20:13 UTC | EQUIFAX INC EFX · Entity 3235 | SaleCommon Stock | 429 | $200.78 | $86,132.73 |
DisclosureSEC source: 0001225208-22-006227 · doc4.xml · nonDerivative · entry 1 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,263 F1 · kind: The sales reported in this Form 4 were effected pursuant to a rule 10b5-1 trading plan adopted by the reporting person on 2/16/2022. F2 · price: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $200.28 to $201.12, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. F3 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date. Read SEC document |
| March 31, 2022 Filed Apr 1, 2022 20:15 UTC | NCR Voyix Corp NCR · Entity 293 | GrantPhantom Stock Units · Derivative | 1,105 | $40.19 | $44,409.95 |
DisclosureSEC source: 0001209191-22-021981 · doc4.xml · derivative · entry 1 Begor Mark W · CIK 0001335111 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,105 Underlying: Common Stock · 1,105 shares Expires not disclosed F1 · security: These are stock units acquired under the NCR Director Compensation Program (the "Compensation Program") as part of the reporting person's annual retainer, which is paid quarterly. The reporting person elected to defer receipt of the annual retainer in accordance with the terms of the Compensation Program. F2 · derivative.exercise_price: The phantom stock units are converted into common stock on a one-for-one basis. F3 · derivative.exercise_date: The phantom stock units become payable in common stock following the reporting person's termination of service as a director. F3 · derivative.expiration_date: The phantom stock units become payable in common stock following the reporting person's termination of service as a director. Read SEC document |
| February 22, 2022 Filed Feb 24, 2022 21:10 UTC | EQUIFAX INC EFX · Entity 3235 | Tax withholdingCommon Stock | 46,485 | $212.24 | $9,865,976.40 |
DisclosureSEC source: 0001225208-22-003259 · doc4.xml · nonDerivative · entry 2 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,635 F1 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date. Read SEC document |
| February 22, 2022 Filed Feb 24, 2022 21:10 UTC | EQUIFAX INC EFX · Entity 3235 | GrantCommon Stock | 86,818 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-003259 · doc4.xml · nonDerivative · entry 1 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,120 F1 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date. Read SEC document |
| February 11, 2022 Filed Feb 15, 2022 22:34 UTC | EQUIFAX INC EFX · Entity 3235 | GrantStock Option/Right to Buy · Derivative | 17,522 | $0.00 Strike: $270.50 | $0.00 |
DisclosureSEC source: 0001225208-22-002197 · doc4.xml · derivative · entry 5 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,522 Underlying: Common Stock · 17,522 shares Expires 2029-02-11 F3 · derivative.exercise_date: Annual equity grant pursuant to the Company's long-term incentive plan. The option vests 100% on December 31, 2025. Read SEC document |
| February 11, 2022 Filed Feb 15, 2022 22:34 UTC | EQUIFAX INC EFX · Entity 3235 | GrantStock Option/Right to Buy · Derivative | 19,649 | $0.00 Strike: $247.50 | $0.00 |
DisclosureSEC source: 0001225208-22-002197 · doc4.xml · derivative · entry 4 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,649 Underlying: Common Stock · 19,649 shares Expires 2029-02-11 F3 · derivative.exercise_date: Annual equity grant pursuant to the Company's long-term incentive plan. The option vests 100% on December 31, 2025. Read SEC document |
| February 11, 2022 Filed Feb 15, 2022 22:34 UTC | EQUIFAX INC EFX · Entity 3235 | GrantCommon Stock | 8,978 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002197 · doc4.xml · nonDerivative · entry 1 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,302 F1 · security: Annual equity grant pursuant to the Company's long-term incentive plan. The award of restricted stock units vests 100% on 2/11/2025. F2 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date. Read SEC document |
| January 03, 2022 Filed Jan 5, 2023 22:23 UTC | NCR Voyix Corp NCR · Entity 293 | GrantPhantom Stock Units · Derivative | 1,400 | $23.41 | $32,774.00 |
DisclosureSEC source: 0001209191-23-001962 · doc4.xml · derivative · entry 1 Begor Mark W · CIK 0001335111 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,400 Underlying: Common Stock · 1,400 shares Expires not disclosed F1 · security: These are stock units acquired under the NCR Director Compensation Program (the "Compensation Program") as part of the reporting person's annual retainer, which is paid quarterly. The reporting person elected to defer receipt of the annual retainer in accordance with the terms of the Compensation Program. F2 · derivative.exercise_price: The phantom stock units are converted into common stock on a one-for-one basis. F3 · derivative.exercise_date: The phantom stock units become payable in common stock following the reporting person's termination of service as a director. F3 · derivative.expiration_date: The phantom stock units become payable in common stock following the reporting person's termination of service as a director. Read SEC document |
| December 31, 2021 Filed Jan 4, 2022 22:09 UTC | NCR Voyix Corp NCR · Entity 293 | GrantPhantom Stock Units · Derivative | 1,104 | $40.20 | $44,380.80 |
DisclosureSEC source: 0001209191-22-000966 · doc4.xml · derivative · entry 1 Begor Mark W · CIK 0001335111 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,104 Underlying: Common Stock · 1,104 shares Expires not disclosed F1 · security: These are stock units acquired under the NCR Director Compensation Program (the "Compensation Program") as part of the reporting person's annual retainer, which is paid quarterly. The reporting person elected to defer receipt of the annual retainer in accordance with the terms of the Compensation Program. F2 · derivative.exercise_price: The phantom stock units are converted into common stock on a one-for-one basis. F3 · derivative.exercise_date: The phantom stock units become payable in common stock following the reporting person's termination of service as a director. F3 · derivative.expiration_date: The phantom stock units become payable in common stock following the reporting person's termination of service as a director. Read SEC document |
| September 30, 2021 Filed Oct 4, 2021 20:14 UTC | NCR Voyix Corp NCR · Entity 293 | GrantPhantom Stock Units · Derivative | 1,145 | $38.76 | $44,380.20 |
DisclosureSEC source: 0001209191-21-058935 · doc4.xml · derivative · entry 1 Begor Mark W · CIK 0001335111 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,145 Underlying: Common Stock · 1,145 shares Expires not disclosed F1 · security: These are stock units acquired under the NCR Director Compensation Program (the "Compensation Program") as part of the reporting person's annual retainer, which is paid quarterly. The reporting person elected to defer receipt of the annual retainer in accordance with the terms of the Compensation Program. F2 · derivative.exercise_price: The phantom stock units are converted into common stock on a one-for-one basis. F3 · derivative.exercise_date: The phantom stock units become payable in common stock following the reporting person's termination of service as a director. F3 · derivative.expiration_date: The phantom stock units become payable in common stock following the reporting person's termination of service as a director. Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 20:20 UTC | NCR Voyix Corp NCR · Entity 293 | GrantPhantom Stock Units · Derivative | 973 | $45.61 | $44,378.53 |
DisclosureSEC source: 0001209191-21-044958 · doc4.xml · derivative · entry 1 Begor Mark W · CIK 0001335111 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 973 Underlying: Common Stock · 973 shares Expires not disclosed F1 · security: These are stock units acquired under the NCR Director Compensation Program (the "Compensation Program") as part of the reporting person's annual retainer, which is paid quarterly. The reporting person elected to defer receipt of the annual retainer in accordance with the terms of the Compensation Program. F2 · derivative.exercise_price: The phantom stock units are converted into common stock on a one-for-one basis. F3 · derivative.exercise_date: The phantom stock units become payable in common stock following the reporting person's termination of service as a director. F3 · derivative.expiration_date: The phantom stock units become payable in common stock following the reporting person's termination of service as a director. Read SEC document |
| May 04, 2021 Filed May 6, 2021 20:10 UTC | EQUIFAX INC EFX · Entity 3235 | Tax withholdingCommon Stock | 75,479 | $237.01 | $17,889,277.79 |
DisclosureSEC source: 0001225208-21-007669 · doc4.xml · nonDerivative · entry 2 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,008 F1 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date. Read SEC document |
| May 04, 2021 Filed May 6, 2021 20:10 UTC | EQUIFAX INC EFX · Entity 3235 | GrantCommon Stock | 128,264 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-007669 · doc4.xml · nonDerivative · entry 1 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,487 F1 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date. Read SEC document |
| April 20, 2021 Filed Apr 22, 2021 20:54 UTC | NCR Voyix Corp NCR · Entity 293 | GrantCommon Stock | 5,599 | $40.19 | $225,023.81 |
DisclosureSEC source: 0001209191-21-027955 · doc4.xml · nonDerivative · entry 1 Begor Mark W · CIK 0001335111 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,796 F1 · security: These restricted stock units represent the annual equity grant awarded to directors under the NCR Director Compensation Program (the "Compensation Program"). The restricted stock units vest in four equal quarterly installments beginning three months after the grant date, subject to the reporting person's continued service as a director on each vesting date. The reporting person elected to defer receipt of NCR common stock underlying the restricted stock units in accordance with the terms of the Compensation Program. The reporting person will receive NCR common stock following the termination of the reporting person's service as a director. Read SEC document |
| March 31, 2021 Filed Apr 1, 2021 20:55 UTC | NCR Voyix Corp NCR · Entity 293 | GrantPhantom Stock Units · Derivative | 653 | $37.95 | $24,781.35 |
DisclosureSEC source: 0001209191-21-024133 · doc4.xml · derivative · entry 1 Begor Mark W · CIK 0001335111 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 653 Underlying: Common Stock · 653 shares Expires not disclosed F1 · security: These are stock units acquired under the NCR Director Compensation Program (the "Compensation Program") as part of the reporting person's annual retainer, which is paid quarterly. The reporting person elected to defer receipt of the annual retainer in accordance with the terms of the Compensation Program. F2 · derivative.exercise_price: The phantom stock units are converted into common stock on a one-for-one basis. F3 · derivative.exercise_date: The phantom stock units become payable in common stock following the reporting person's termination of service as a director. F3 · derivative.expiration_date: The phantom stock units become payable in common stock following the reporting person's termination of service as a director. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 22:21 UTC | EQUIFAX INC EFX · Entity 3235 | GrantStock Option/Right to Buy · Derivative | 26,751 | $0.00 Strike: $194.91 | $0.00 |
DisclosureSEC source: 0001225208-21-002787 · doc4.xml · derivative · entry 3 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,751 Underlying: Common Stock · 26,751 shares Expires 2028-02-12 F3 · derivative.exercise_date: Annual equity grant pursuant to the Company's long-term incentive plan. The option vests 100% on December 31, 2025. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 22:21 UTC | EQUIFAX INC EFX · Entity 3235 | GrantStock Option/Right to Buy · Derivative | 30,596 | $0.00 Strike: $212.63 | $0.00 |
DisclosureSEC source: 0001225208-21-002787 · doc4.xml · derivative · entry 2 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,596 Underlying: Common Stock · 30,596 shares Expires 2028-02-12 F3 · derivative.exercise_date: Annual equity grant pursuant to the Company's long-term incentive plan. The option vests 100% on December 31, 2025. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 22:21 UTC | EQUIFAX INC EFX · Entity 3235 | GrantCommon Stock | 11,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-002787 · doc4.xml · nonDerivative · entry 1 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,046 F1 · security: Annual equity grant pursuant to the Company's long-term incentive plan. The award of restricted stock units vests 100% on 2/12/2024. F2 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date. Read SEC document |
| December 31, 2020 Filed Jan 5, 2021 21:17 UTC | NCR Voyix Corp NCR · Entity 293 | GrantPhantom Stock Units · Derivative | 659 | $37.57 | $24,758.63 |
DisclosureSEC source: 0001209191-21-001026 · doc4.xml · derivative · entry 1 Begor Mark W · CIK 0001335111 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 659 Underlying: Common Stock · 659 shares Expires not disclosed F1 · security: These are stock units acquired under the NCR Director Compensation Program (the "Compensation Program") as part of the reporting person's annual retainer, which is paid quarterly. The reporting person elected to defer receipt of the annual retainer in accordance with the terms of the Compensation Program. F2 · derivative.exercise_price: The phantom stock units are converted into common stock on a one-for-one basis. F3 · derivative.exercise_date: The phantom stock units become payable in common stock following the reporting person's termination of service as a director. F3 · derivative.expiration_date: The phantom stock units become payable in common stock following the reporting person's termination of service as a director. Read SEC document |
| September 30, 2020 Filed Oct 1, 2020 20:10 UTC | NCR Voyix Corp NCR · Entity 293 | GrantPhantom Stock Units · Derivative | 1,118 | $22.14 | $24,752.52 |
DisclosureSEC source: 0001209191-20-052606 · doc4.xml · derivative · entry 1 Begor Mark W · CIK 0001335111 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,118 Underlying: Common Stock · 1,118 shares Expires not disclosed F1 · security: These are stock units acquired under the NCR Director Compensation Program (the "Compensation Program") as part of the reporting person's annual retainer, which is paid quarterly. The reporting person elected to defer receipt of the annual retainer in accordance with the terms of the Compensation Program. F2 · derivative.exercise_price: The phantom stock units are converted into common stock on a one-for-one basis. F3 · derivative.exercise_date: The phantom stock units become payable in common stock following the reporting person's termination of service as a director. F3 · derivative.expiration_date: The phantom stock units become payable in common stock following the reporting person's termination of service as a director. Read SEC document |
| June 30, 2020 Filed Jul 1, 2020 20:03 UTC | NCR Voyix Corp NCR · Entity 293 | GrantPhantom Stock Units · Derivative | 1,429 | $17.32 | $24,750.28 |
DisclosureSEC source: 0001209191-20-039707 · doc4.xml · derivative · entry 1 Begor Mark W · CIK 0001335111 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,429 Underlying: Common Stock · 1,429 shares Expires not disclosed F1 · security: These are stock units acquired under the NCR Director Compensation Program (the "Compensation Program") as part of the reporting person's annual retainer, which is paid quarterly. The reporting person elected to defer receipt of the annual retainer in accordance with the terms of the Compensation Program. F2 · derivative.exercise_price: The phantom stock units are converted into common stock on a one-for-one basis. F3 · derivative.exercise_date: The phantom stock units become payable in common stock following the reporting person's termination of service as a director. F3 · derivative.expiration_date: The phantom stock units become payable in common stock following the reporting person's termination of service as a director. Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 20:10 UTC | NCR Voyix Corp NCR · Entity 293 | GrantCommon Stock | 12,858 | $17.50 | $225,015.00 |
DisclosureSEC source: 0001209191-20-025421 · doc4.xml · nonDerivative · entry 1 Begor Mark W · CIK 0001335111 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,197 F1 · security: These restricted stock units represent the annual equity grant awarded to directors under the NCR Director Compensation Program (the "Compensation Program"). The restricted stock units vest in four equal quarterly installments beginning three months after the grant date, subject to the reporting person's continued service as a director on each vesting date. The reporting person elected to defer receipt of NCR common stock underlying the restricted stock units in accordance with the terms of the Compensation Program. The reporting person will receive NCR common stock following the termination of the reporting person's service as a director. Read SEC document |
| March 31, 2020 Filed Apr 2, 2020 20:24 UTC | NCR Voyix Corp NCR · Entity 293 | GrantPhantom Stock Units · Derivative | 233 | $17.70 | $4,124.10 |
DisclosureSEC source: 0001209191-20-022557 · doc4.xml · derivative · entry 1 Begor Mark W · CIK 0001335111 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 233 Underlying: Common Stock · 233 shares Expires not disclosed F1 · security: These are stock units acquired under the NCR Director Compensation Program (the "Compensation Program") as part of the reporting person's annual retainer, which is paid quarterly. The reporting person elected to defer receipt of the annual retainer in accordance with the terms of the Compensation Program. F2 · derivative.exercise_price: The phantom stock units are converted into common stock on a one-for-one basis. F3 · derivative.exercise_date: The phantom stock units become payable in common stock following the reporting person's termination of service as a director. F3 · derivative.expiration_date: The phantom stock units become payable in common stock following the reporting person's termination of service as a director. Read SEC document |
| March 01, 2020 Filed Mar 3, 2020 21:28 UTC | NCR Voyix Corp NCR · Entity 293 | GrantCommon Stock | 1,339 | $25.20 | $33,742.80 |
DisclosureSEC source: 0001209191-20-015169 · doc4.xml · nonDerivative · entry 1 Begor Mark W · CIK 0001335111 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,339 F1 · security: These restricted stock units represent the equity grant awarded to the reporting person under the NCR Director Compensation Program. The restricted stock units will vest in full on April 24, 2020, subject to the reporting person's continued service as a director through the date of the NCR 2020 Annual Meeting of Stockholders. Read SEC document |
| March 01, 2020 Filed Apr 2, 2020 20:21 UTC Amendment | NCR Voyix Corp NCR · Entity 293 | GrantCommon Stock | 1,339 | $25.20 | $33,742.80 |
DisclosureSEC source: 0001209191-20-022553 · doc4a.xml · nonDerivative · entry 1 Begor Mark W · CIK 0001335111 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,339 F1 · security: These restricted stock units represent the equity grant awarded to the reporting person under the NCR Director Compensation Program (the "Compensation Program"). The restricted stock units will vest in full on April 24,2020, subject to the reporting person's continued service as a director through the date of the NCR 2020 Annual Meeting of Stockholders. F2 · security: This amended Form 4 discloses that in accordance with the terms of the Compensation Program, the reporting person elected to defer receipt of 818 of the 1,339 restricted stock units previously reported on Form 4 on March 3, 2020. The reporting person will receive the underlying 818 shares of NCR common stock following the termination of his service as a Director. All other information in the previous Form 4 remains unchanged. No other Form 4s by the reporting person are impacted by this amendment. Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 21:55 UTC | EQUIFAX INC EFX · Entity 3235 | GrantStock Option/Right to Buy · Derivative | 44,321 | $0.00 Strike: $175.48 | $0.00 |
DisclosureSEC source: 0001225208-20-003457 · doc4.xml · derivative · entry 3 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,321 Underlying: Common Stock · 44,321 shares Expires 2026-02-21 F3 · derivative.exercise_date: Annual equity grant pursuant to the Company's long-term incentive plan. The option vests in three equal annual increments beginning 2/21/2021. Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 21:55 UTC | EQUIFAX INC EFX · Entity 3235 | GrantStock Option/Right to Buy · Derivative | 55,919 | $0.00 Strike: $191.44 | $0.00 |
DisclosureSEC source: 0001225208-20-003457 · doc4.xml · derivative · entry 2 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,919 Underlying: Common Stock · 55,919 shares Expires 2026-02-21 F3 · derivative.exercise_date: Annual equity grant pursuant to the Company's long-term incentive plan. The option vests in three equal annual increments beginning 2/21/2021. Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 21:55 UTC | EQUIFAX INC EFX · Entity 3235 | GrantCommon Stock | 12,694 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-003457 · doc4.xml · nonDerivative · entry 1 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,003 F1 · security: Annual equity grant pursuant to the Company's long-term incentive plan. The award of restricted stock units vests 100% on 2/21/2023. F2 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date. Read SEC document |
| February 22, 2019 Filed Feb 27, 2019 01:30 UTC | EQUIFAX INC EFX · Entity 3235 | GrantStock Option/Right to Buy · Derivative | 63,597 | $0.00 Strike: $127.37 | $0.00 |
DisclosureSEC source: 0001225208-19-003799 · doc4.xml · derivative · entry 4 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,597 Underlying: Common Stock · 63,597 shares Expires 2025-02-22 F3 · security: Annual equity grant pursuant to the Company's long-term incentive plan. The option vests 100% on 2/22/2022. Read SEC document |
| February 22, 2019 Filed Feb 27, 2019 01:30 UTC | EQUIFAX INC EFX · Entity 3235 | GrantStock Option/Right to Buy · Derivative | 76,895 | $0.00 Strike: $138.45 | $0.00 |
DisclosureSEC source: 0001225208-19-003799 · doc4.xml · derivative · entry 3 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,895 Underlying: Common Stock · 76,895 shares Expires 2025-02-22 F3 · security: Annual equity grant pursuant to the Company's long-term incentive plan. The option vests 100% on 2/22/2022. Read SEC document |
| February 22, 2019 Filed Feb 27, 2019 01:30 UTC | EQUIFAX INC EFX · Entity 3235 | GrantStock Option/Right to Buy · Derivative | 92,712 | $0.00 Strike: $149.53 | $0.00 |
DisclosureSEC source: 0001225208-19-003799 · doc4.xml · derivative · entry 2 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,712 Underlying: Common Stock · 92,712 shares Expires 2025-02-22 F3 · security: Annual equity grant pursuant to the Company's long-term incentive plan. The option vests 100% on 2/22/2022. Read SEC document |
| February 22, 2019 Filed Feb 27, 2019 01:30 UTC | EQUIFAX INC EFX · Entity 3235 | GrantCommon Stock | 15,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-003799 · doc4.xml · nonDerivative · entry 1 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,670 F1 · security: Annual equity grant pursuant to the Company's long-term incentive plan. The award of restricted stock units vests 100% on 2/22/2022. F2 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date. Read SEC document |
| May 25, 2018 Filed May 30, 2018 20:21 UTC | EQUIFAX INC EFX · Entity 3235 | PurchaseCommon Stock | 8,700 | $115.01 | $1,000,627.02 |
DisclosureSEC source: 0001225208-18-009971 · doc4.xml · nonDerivative · entry 1 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,491 F1 · price: The price reported in column 4 is a weighted average price. The shares were purchased at prices ranging from $114.9500 to $115.0963, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. Read SEC document |
| May 04, 2018 Filed May 8, 2018 20:26 UTC | EQUIFAX INC EFX · Entity 3235 | GrantStock Option/Right to Buy · Derivative | 62,246 | $0.00 Strike: $112.46 | $0.00 |
DisclosureSEC source: 0001225208-18-008890 · doc4.xml · derivative · entry 4 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,165 Underlying: Common Stock · 62,246 shares Expires 2028-05-04 F4 · derivative.exercise_date: Initial equity grant pursuant to the Company's long-term incentive plan. The option vests in three equal annual increments beginning 5/4/2019. Read SEC document |
| May 04, 2018 Filed May 8, 2018 20:26 UTC | EQUIFAX INC EFX · Entity 3235 | GrantStock Option/Right to Buy · Derivative | 88,919 | $0.00 Strike: $112.46 | $0.00 |
DisclosureSEC source: 0001225208-18-008890 · doc4.xml · derivative · entry 3 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,919 Underlying: Common Stock · 88,919 shares Expires 2028-05-04 F3 · derivative.exercise_date: One-time special equity grant pursuant to the Company's long-term incentive plan. The option vests in three equal annual increments beginning 5/4/2019. Read SEC document |
| May 04, 2018 Filed May 8, 2018 20:26 UTC | EQUIFAX INC EFX · Entity 3235 | GrantCommon Stock | 15,561 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-008890 · doc4.xml · nonDerivative · entry 2 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,791 F2 · security: Initial equity grant pursuant to the Company's long-term incentive plan. The award of restricted stock units vests 100% on 5/4/2021. Read SEC document |
| May 04, 2018 Filed May 8, 2018 20:26 UTC | EQUIFAX INC EFX · Entity 3235 | GrantCommon Stock | 22,230 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-008890 · doc4.xml · nonDerivative · entry 1 Begor Mark W · CIK 0001335111 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,230 F1 · security: One-time special equity grant pursuant to the Company's long-term incentive plan. The award of restricted stock units vests 100% on 5/4/2021. Read SEC document |
| March 21, 2018 Filed Mar 22, 2018 18:28 UTC | FAIR ISAAC CORP FICO · Entity 3206 | Exercise / conversionRestricted Stock Units · Derivative | 1,587 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-18-002283 · marketforms-41301.xml · derivative · entry 2 Begor Mark W · CIK 0001335111 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,586 Underlying: Common Stock · 1,587 shares Expires 2019-03-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a right to receive one share of Fair Isaac common stock contingent upon continued service on the board. F2 · derivative.exercise_date: The restricted stock units vest in three equal annual installments commencing on this date and vested shares will be delivered to the reporting person as soon as practicable thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.